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ABSTRACT 
The optimized reverse phase high performance liquid chromatographic method was developed for estimation of Brimonidine 
Tartrate in bulk drug and pharmaceutical dosage form. Chromatography was performed on Kromasil C 18 ( 250 mm X 4.6 mm i.d. , 
5 μm particle size) column with mobile phase citric acid monohydrate buffer:water:methanol (30:50:20 v/v/v) and  pH 3 was 
maintained by using triethylamine. The flow rate was 1.0 ml/min. Elute was detected at 246 nm and it effectively separated at 
Retention Time of 5.96 min. The LOD and LOQ was 1.47 and 4.47 μg/ml respectively. A linear response was observed over the 
concentration range 40-80 μg/ml for Brimonidine Tartrate. Thus the proposed HPLC method was found accurate, specific, precise, 
robust and reproducible. 
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INTRODUCTION: 
Brimonidine Tartrate is used in the treatment of open-
angle glaucoma or ocular hypertension. It is selective 
alpha-2 adrenergic receptor agonist. Chemically it is 5-
bromo-6-(2-imidazolidinylideneamino) quinoxaline L-
tartrate. No significant HPLC method reports were 
found for estimation of Brimonidine Tartrate in 
pharmaceutical formulation while few HPTLC, HPLC, 
LC-MS, HILIC (Hydrophilic interaction liquid 
chromatography) methods reported for the estimation of 
Brimonidine Tartrate in blood serum and in ocular fluids 
(Rahore, 2010, Phogat, 2011, Jiang, 2009, Sethi 2001). 
The aim of study was to develope and validates simple, 
specific, sensitive, accurate and precise HPLC method 
for determination of Brimonidine Tartrate in ophthalmic 
formulation as per International Conference on 
Harmonization (ICH) guidelines (ICH, 2005). 
MATERIAL AND METHODS: 
Apparatus  
A Shimadzu RP-HPLC instrument ( LC -20 AD as Per 
21 CFR) equipped with an photodiode array detector, 
manual injector with 20 μl loop, and Kromasil C18 
column (250 mm × 4.6 mm id, 5 μm particle size) and 
LC- solution software was used. Contech CB-50 
analytical balance and ultra sonic cleaner (Spetralab, 
UCB-40) were used during the study. 
 
Figure 1: Structure of Brimonidine Tartrate 
Reagents and materials  
Brimonidine Tartrate was received as gift sample from 
Cipla Ltd., (Mumbai, Maharashtra).  HPLC grade 
methanol (Qualigens), citric acid monohydrate buffer 
was of AR grade and water for RP-HPLC was prepared 
by double glass distillation and filtered through nylon 
membrane filter 0.45 μm (Pall Lab Sci). 
Chromatographic conditions 
Kromasil C18 Column (250 mm × 4.6 mm id, 5 μm 
particle size) was used at ambient temperature. The 
mobile phase consisted of citric acid monohydrate 
buffer: water: methanol (30: 50:20 v/v/v) and pH 3 was 
maintained by triethylamine.  Flow rate was 1.0 ml/min. 
The mobile phase was filtered through a 0.45 μm 
membrane filter and degassed before used. The elution 
was monitored at 246 nm and injection volume was 20 
μl.  
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Preparation of solutions 
Citric Acid Buffer    
Accurately weighed Citric acid monohydrate (1.05 gm) 
was transferred to a beaker (500 ml) and dissolved in 
double distilled water (500 ml). 
The mobile phase was citric acid monohydrate, pH 3: 
water: methanol (30: 50:20)  
Preparation of Standard Stock Solution 
Standard stock solution of Brimonidine Tartrate was 
prepared by dissolving 10 mg of drug in10 ml of 
methanol to get the concentration of 1 mg/ml from 
which 1 ml was further diluted to 10 ml with methanol 
to obtain a working standard having a concentration of 
100 μg/μl. 
Determination of wavelength of maximum 
absorbance 
The standard solutions of Brimonidine Tartrate were 
scanned in the range of 200-400 nm against buffer 
solution as a blank. Brimonidine Tartrate showed 
maximum absorbance at 246nm. So the wavelength 
selected for the determination of Brimonidine Tartrate 
was 246 nm. 
Method Validation (ICH, 2005) 
Calibration curve (Linearity) 
Calibration curve was plotted over concentration range 
of 40-80 ug/ml for Brimonidine Tartrate.  Accurately 
measured standard stock solution of Brimonidine 
Tartrate (4, 5, 6, 7 and 8 ml) was transferred to a series 
of 10 ml volumetric flask and volume in each flask was 
adjusted 10 ml with mobile phase. Resulting solution 
were injected into the column and the peak area obtained 
at flow rate of 1.0 ml per minute for Brimonidine 
Tartrate. Calibration curve was constructed for 
Brimonidine Tartrate by plotting peak area versus 
concentration at 246 nm. Each reading was average of 
three determinations. 
Accuracy (% Recovery) 
To check the accuracy of the method, recovery studies 
were carried out by addition of formulation to pre-
analyzed sample solution at three different levels 80, 100 
and 120 %. Chromatogram was obtained and the peak 
areas were noted. At each level of the amount, three 
determinations were carried out. 
Limit of Detection and Limit of Quantification 
The limit of detection (LOD) and limit of Quantification 
(LOQ) for Brimonidine Tratrate was derived by 
calculating signal-to-noise ratio (S/N, i.e. 3.3 for LOD 
and 10 for LOQ) and using following equation as per 
International Conference on Harmonization (ICH) 
guidelines. 
LOD = 3.3 × σ/S 
LOQ = 10 × σ/S 
Where σ = the standard deviation of the responses and 
S = Slope of calibration curve. 
Specificity and System Suitability 
Specificity is the ability to assess unequivocally the 
analyte in the presence of components, which may be 
expected to be present. Typically these might include 
impurities, degradants, matrix etc.  
One blank and one standard preparation was injected 
and chromatograms were recorded which is further 
calculated for system suitability parameters. 
Robustness 
Robustness studies were carried out by examining the 
effect of small, deliberate variation of the analytical 
conditions on the peak areas of the drug. Factors varied 
were volume of mobile phase (± 3 ml), wavelength (±2 
nm) and flow rate (± 0.2 ml/min). One factor at a time 
was changed to study the effect. 
Intra-day and Inter-day precision 
The intra-day precision was determined by analyzing 
standard solution of Brimonidine Tartrate at 60 ug/ml 
concentration for six replicates on the same day while 
inter-day precision was determind by analysing 
corresponding standard on two different days over a 
period of one week. 
RESULT AND DISCUSSION: 
To optimize the RP-HPLC parameters, several mobile 
phase compositions were tried. A satisfactory separation 
and good peak symmetry was found in a mixture of 
citric acid monohydrate buffer pH 3, methanol and water 
(30:20:50) at 1.0 ml/min flow rate. As it was shown in 
Figure 2, the optimum wavelength for detection was set 
at 246 nm at which much better detector responses for 
Brimonidine Tartrate was obtained.  The retention time 
was 5.962 min as reported in Figure 3. 
 
 
 
Figure 2: Maximum detection wavelength of 
Brimonidine Tartrate 
Figure 3: Typical RP- HPLC Chromatogram Brimonidine 
Tartrate (40 ug /ml) with corresponding retention  time. 
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Chromatographic conditions are outlined in Table 1. 
The calibration graph for Brimonidine Tartrate was 
constructed by plotting the peak area versus their 
corresponding concentrations; good linearity was found 
over the range 40-80 μg/ml. The calibration graph is 
shown in Figure 4. 
 
Table 1:  Chromatographic conditions 
Parameter  Observation 
Mobile phase 0.01 Mol/L Citric acid monohydrate: Methanol : Water (30:20:50) 
pH   3 maintained by using triethylamine 
Column Kromasil – C 18 Column (250 mm × 6.5 mm × 5 um) 
Flow rate 1 ml/min 
Detection wavelength 246 nm 
Injection volume 20 µl 
Run time 10 Minutes 
Retention time 5.96  mins 
 
 
Figure 4: Calibration Curve of Brimonidine Tartrate 
The proposed method has been applied to the assay of 
Brimonidine Tartrate in pharmaceutical dosage form. 
The results obtained indicate the additives present do 
not interfere with analysis of the studied formulation. 
System suitability test parameters for Brimonidine 
Tartrate for the RP-HPLC method are reported in Table 
2. The optical and regression characteristics and 
validation parameters are reported in Table 3. Data of 
recovery study is shown in Table 4. The robustness 
study is reported in Table 5. 
On the basis of series of investigation the optimized 
method can be routinely use for analysis purpose.
 
Table 2:  System suitability testing of the HPLC method 
System suitability Parameters Observation Acceptance Criteria 
Peak Area  3419885 - 
Tailing Factor 1.49 NMT 2 
Column Efficiency  5861 NLT 2500 
% R.S.D. 0.7425 NMT 2 
 
Table 3:  The optical and regression characteristics and validation parameters of HPLC method for analysis of 
Brimonidine tartrate 
Parameter Observation 
Calibration range 40-80 μg/ml 
Detection limit       1.477 μg/ml 
Quantitation limit 4.476 μg/ml 
Slope 85830 
Intercept 17081 
Correlation coefficient 0.999 
Intraday RSD, % 0.7425 
Interday RSD, % Day 1 -0.7425 
Day 2- 0.4202 
 
Table 4:  Data of recovery study for Brimonidine Tartrate by HPLC method 
Amount taken 
(μg/ml) 
Amount added 
(μg/ml) 
Amount found % Recovery 
25 20 45.17 100.39 
25 25 49.48 98.96 
25 30 54.18 98.52 
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Table 5:  Data of robustness study for Brimonidine Tartrate by HPLC method 
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Experiment % RSD Theoretical plates Tailing factor 
(+) Wavelength 0.244 5713 1.50 
(-)  Wavelength 0.167 5992 1.49 
(+)Flow rate 0.549 5760 1.40 
(-)  Flow rate 1.300 6091 1.61 
(+) Mobile phase  volume 0.303 7065 1.46 
(-)  Mobile phase volume 0.653 5041 1.51 
